Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RAPPNASDAQ:SNDLNASDAQ:STOKNASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRAPPRapport Therapeutics$8.98+3.0%$11.49$6.43▼$29.74$327.73MN/A180,112 shs134,789 shsSNDLSNDL$1.39+9.4%$1.61$1.24▼$2.93$365.26M3.232.69 million shs2.08 million shsSTOKStoke Therapeutics$6.43+9.0%$8.68$5.36▼$17.58$347.72M1.09719,054 shs1.15 million shsVXRTVaxart$0.33+7.6%$0.54$0.29▼$1.07$75.26M1.572.40 million shs2.37 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRAPPRapport Therapeutics-8.31%-8.79%+1.51%-47.75%+871,999,900.00%SNDLSNDL-4.51%-11.81%-18.59%-32.45%-44.05%STOKStoke Therapeutics-1.83%-5.30%-26.34%-34.15%-54.62%VXRTVaxart-1.48%-17.72%-34.76%-62.13%-71.62%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRAPPRapport Therapeutics1.7859 of 5 stars3.50.00.00.03.11.70.6SNDLSNDL3.6065 of 5 stars3.55.00.00.03.10.01.3STOKStoke Therapeutics3.0359 of 5 stars3.60.00.04.81.31.70.0VXRTVaxart2.1915 of 5 stars3.53.00.00.02.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRAPPRapport Therapeutics 3.00Buy$32.67263.77% UpsideSNDLSNDL 3.00Buy$3.63160.79% UpsideSTOKStoke Therapeutics 3.13Buy$24.67283.62% UpsideVXRTVaxart 3.00Buy$3.00809.64% UpsideCurrent Analyst Ratings BreakdownLatest VXRT, SNDL, RAPP, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$28.004/8/2025RAPPRapport TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMkt Outperform3/27/2025VXRTVaxartB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $2.003/19/2025SNDLSNDLATB CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price Target$3.50 ➝ $4.003/19/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.003/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.003/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.002/19/2025STOKStoke TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.002/18/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$35.00 ➝ $47.002/18/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 4/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ASNDLSNDL$920.45M0.40N/AN/A$3.47 per share0.40STOKStoke Therapeutics$36.56M9.51N/AN/A$3.57 per share1.80VXRTVaxart$28.70M2.62N/AN/A$0.38 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRAPPRapport Therapeutics-$34.79M-$13.84N/AN/AN/AN/AN/AN/A6/2/2025 (Estimated)SNDLSNDL-$127.91M-$0.26N/AN/AN/A-12.11%-8.27%-6.96%5/14/2025 (Estimated)STOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%5/5/2025 (Estimated)VXRTVaxart-$82.46M-$0.34N/AN/AN/A-431.61%-110.46%-62.78%5/12/2025 (Estimated)Latest VXRT, SNDL, RAPP, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025STOKStoke Therapeutics-$0.42N/AN/AN/A$27.37 millionN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million3/20/2025Q4 2024VXRTVaxart-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million3/18/2025Q4 2024SNDLSNDL-$0.01-$0.19-$0.18-$0.19$248.10 million$179.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRAPPRapport TherapeuticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRAPPRapport TherapeuticsN/A45.9145.91SNDLSNDL0.105.614.16STOKStoke TherapeuticsN/A5.095.09VXRTVaxartN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRAPPRapport TherapeuticsN/ASNDLSNDLN/ASTOKStoke TherapeuticsN/AVXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipRAPPRapport TherapeuticsN/ASNDLSNDLN/ASTOKStoke Therapeutics11.30%VXRTVaxart2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ASNDLSNDL580262.78 millionN/AOptionableSTOKStoke Therapeutics10054.08 million46.98 millionOptionableVXRTVaxart120228.21 million221.57 millionOptionableVXRT, SNDL, RAPP, and STOK HeadlinesRecent News About These CompaniesCritical Review: NKGen Biotech (NYSE:NKGN) vs. Vaxart (NASDAQ:VXRT)April 2, 2025 | americanbankingnews.comB. Riley Comments on Vaxart's Q1 Earnings (NASDAQ:VXRT)March 31, 2025 | americanbankingnews.comB. Riley Issues Positive Outlook for Vaxart EarningsMarch 31, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. RileyMarch 28, 2025 | marketbeat.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPSMarch 21, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Issues Earnings ResultsMarch 21, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comVAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue EstimatesMarch 20, 2025 | zacks.comVaxart Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Short Interest UpdateMarch 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?March 14, 2025 | marketbeat.comVaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20March 14, 2025 | markets.businessinsider.comVaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025March 13, 2025 | quiverquant.comVaxart announces trial initiation of norovirus oral pill vaccine candidateMarch 11, 2025 | markets.businessinsider.comVaxart, Inc. Launches Phase 1 Clinical Trial for Second-Generation Oral Norovirus Vaccine ConstructsMarch 11, 2025 | quiverquant.comVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateMarch 11, 2025 | globenewswire.comVaxart (VXRT) to Release Earnings on ThursdayMarch 11, 2025 | marketbeat.comVaxart announces norovirus vaccine candidate trial data publishedMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVXRT, SNDL, RAPP, and STOK Company DescriptionsRapport Therapeutics NASDAQ:RAPP$8.98 +0.26 (+2.98%) Closing price 04:00 PM EasternExtended Trading$8.99 +0.01 (+0.17%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.SNDL NASDAQ:SNDL$1.39 +0.12 (+9.45%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Stoke Therapeutics NASDAQ:STOK$6.43 +0.53 (+8.98%) Closing price 04:00 PM EasternExtended Trading$6.38 -0.04 (-0.70%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Vaxart NASDAQ:VXRT$0.33 +0.02 (+7.60%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.00 (+1.27%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Alphabet a Generational Buying Opportunity at These Levels? Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder? Amazon Stock Bounces From Lows as Smart Money Steps In Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
